

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE  
SECURITIES EXCHANGE ACT OF 1934**

Dated February, 2016

Commission File Number 001-36421

---

**AURINIA PHARMACEUTICALS INC.**

(Exact name of Registrant as specified in its charter)

---

N/A

(Translation of Registrant's Name)

#1203-4464 Markham Street  
Victoria, British Columbia  
V8Z7X8

(250) 708-4272

(Address and telephone number of registrant's principle executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: February 4, 2016

**Aurinia Pharmaceuticals Inc.**

By: /s/ Michael R. Martin

\_\_\_\_\_  
Name: Michael R. Martin

Title: Chief Operating Officer

EXHIBIT INDEX

<u>Exhibit</u>	<u>Description of Exhibit</u>
99.1	News Release – Aurinia Pharmaceuticals to Attend Two Upcoming Investor Conferences

## Aurinia Pharmaceuticals to Attend Two Upcoming Investor Conferences

- *Source Capital Group, 2016 Disruptive Growth & Healthcare Conference*
- *5<sup>th</sup> Annual Leerink Global Healthcare Conference*

VICTORIA, British Columbia--(BUSINESS WIRE)--February 4, 2016--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH / TSX:AUP) today announced that its Chief Operating Officer Michael R. Martin will attend two upcoming investor conferences. A general corporate overview will be provided in presentation format during the Source Capital 2016 Disruptive Growth & Healthcare Conference on February 10<sup>th</sup>, 2016, while a fireside chat & discussion will occur at the 5<sup>th</sup> Annual Leerink Global Healthcare Conference on February 11<sup>th</sup>, 2016. Times for these presentations and discussions are specified as follows:

### *Aurinia Source Capital Presentation Details*

Date: Wednesday, February 10<sup>th</sup>, 2016  
 Time: 4:30 p.m. Eastern Standard Time  
 Location: New York, NY, Convene Conference Centre – Murray Hill Hub  
 Webcast: <http://wsw.com/webcast/sourcecap1/auph>

### *Aurinia 5<sup>th</sup> Annual Leerink Global Healthcare Conference Fireside Chat Details*

Date: Thursday, February 11<sup>th</sup>, 2016  
 Time: 1:50 p.m. Eastern Standard Time  
 Location: New York, NY, Waldorf Astoria Hotel, South Terrace Room  
 Webcast: <http://wsw.com/webcast/leerink26/auph>

Live webcasts of the presentations and discussions will be available at the above coordinates, archived webcasts and materials will also be available on the Company's website at [www.auriniapharma.com](http://www.auriniapharma.com)

### *About Aurinia*

Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently collecting data in its 265 patient Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (LN). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.

Visit [www.auriniapharma.com](http://www.auriniapharma.com) for more information.

### CONTACT:

#### **Company Contact:**

Stephen Zaruby, 250-708-4293  
 President & Chief Executive Officer  
[szaruby@auriniapharma.com](mailto:szaruby@auriniapharma.com)

or

#### **Investor & Media Contact:**

Michael R. Martin, 250-708-4272  
 Chief Operating Officer  
[mmartin@auriniapharma.com](mailto:mmartin@auriniapharma.com)

or

Renmark Financial Communications Inc.  
 Barry Mire, 416-644-2020  
[bmire@renmarkfinancial.com](mailto:bmire@renmarkfinancial.com)

or

Laura Welsh, 514-939-3989  
[lwelsh@renmarkfinancial.com](mailto:lwelsh@renmarkfinancial.com)